首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   12509篇
  免费   718篇
  国内免费   182篇
耳鼻咽喉   105篇
儿科学   754篇
妇产科学   284篇
基础医学   1348篇
口腔科学   202篇
临床医学   1409篇
内科学   2059篇
皮肤病学   301篇
神经病学   178篇
特种医学   150篇
外科学   1030篇
综合类   1227篇
预防医学   2565篇
眼科学   129篇
药学   1162篇
  7篇
中国医学   124篇
肿瘤学   375篇
  2023年   178篇
  2022年   253篇
  2021年   652篇
  2020年   560篇
  2019年   465篇
  2018年   437篇
  2017年   449篇
  2016年   479篇
  2015年   508篇
  2014年   868篇
  2013年   1067篇
  2012年   836篇
  2011年   841篇
  2010年   704篇
  2009年   634篇
  2008年   473篇
  2007年   533篇
  2006年   483篇
  2005年   398篇
  2004年   380篇
  2003年   260篇
  2002年   256篇
  2001年   208篇
  2000年   175篇
  1999年   155篇
  1998年   126篇
  1997年   130篇
  1996年   80篇
  1995年   88篇
  1994年   62篇
  1993年   58篇
  1992年   56篇
  1991年   49篇
  1990年   48篇
  1989年   57篇
  1988年   43篇
  1987年   49篇
  1986年   42篇
  1985年   58篇
  1984年   25篇
  1983年   22篇
  1982年   33篇
  1981年   15篇
  1980年   14篇
  1979年   17篇
  1978年   18篇
  1976年   13篇
  1975年   15篇
  1974年   9篇
  1973年   8篇
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
1.
Tsukamurella species are obligate aerobic, gram-positive, weak acid-fast, nonmotile bacilli. They are found in various environments, such as soil, water, sludge, and petroleum reservoir wastewater, and belong to the order Actinomycetales. In 2016, there was a reclassification of species within the genus Tsukamurella, merging the species Tsukamurella tyrosinosolvens (T. tyrosinosolvens) and Tsukamurella carboxydivorans. Tsukamurella species are clinically considered to be a rare opportunistic pathogen, because most reported cases have been related to bacteremia and intravascular prosthetic devices and immunosuppression. To date, it has been isolated only from human specimens, and has always been associated with clinical disease; human infections are very rare. Reported infections have included pneumonia, brain abscesses, catheter-related bloodstream infections, ocular infections, bacteremia, and sepsis presenting with septic pulmonary emboli in patients who are immunocompromised. To date, there is no commercially available test for identification. On the other hand, sequence-based identification, including matrix-assisted laser desorption ionization time-of-flight mass spectrometry, is an alternative method for identifying clinical isolates that are either slow growers or difficult to identify through biochemical profiling. The golden standards for diagnosis and optimal management still remain to be determined. However, newer molecular biological techniques can provide accurate identification, and contribute to the appropriate selection of definitive therapy for infections caused by this organism. Combinations of several antimicrobial agents have been proposed for treatment, though the length of treatment for infections has yet to be determined, and should be individualized according to clinical response. Immunocompromised patients often experience severe cases due to infection, and life-threatening T. tyrosinosolvens events associated with dissemination and/or failure of source control have occurred. Favorable prognoses can be achieved through earlier identification of the cause of infection, as well as successful management, including appropriate antibiotic therapy together with source control. Further analyses of similar cases are required to establish the most adequate diagnostic methods and treatment regimens for infections.  相似文献   
2.
摘要:目的 通过评估经鼻导管高流量湿化氧疗在肺部感染患者中的临床疗效,为肺部感染尤其是重症肺炎的患者呼吸道管理策略提供一定的参考依据。方法 2015年9月至2017年9月,采用方便抽样方法选取收治于复旦大学附属华山医院感染科的375例肺部感染患者作为研究对象。依据时间将2015年9月1日至2016年8月31日、2016年9月1日至2017年8月31日入院的患者分别纳入对照组和观察组,对照组患者接受常规治疗,观察组患者在对照组的基础上根据病情接受经鼻导管高流量湿化氧疗。比较两组患者的住院时长、气管插管(包括无创/有创气管切开)人数比例以及预后转归。在对照组和观察组的重症肺炎患者中评估接受经鼻导管高流量湿化氧疗的患者预后情况。结果 观察组重症肺炎的患者比例较对照组高,预后较对照组好,均有统计学差异(P < 0.05)。与未使用HFNC治疗的患者比较,发现接受HFNC的重症肺炎患者预后更好,有统计学差异(P < 0.05)。使用HFNC治疗后,重症肺炎患者的多个指标如呼吸频率、心率、氧饱和度、氧分压均有显著改善,均有统计学差异(P < 0.05)。结论 近年来,我院感染科收治患者的肺部感染患者人数越来越多,重症化比例也越来越高。在此情况下,医院的管理、医生的诊疗、护士的护理到位,使整体肺部感染患者的住院天数、预后转归与既往病情较轻的时候并无差异。同时,接受HFNC的重症肺炎患者,预后明显好转,表明HFNC对改善肺部感染患者预后有明显疗效。  相似文献   
3.
4.
5.
BackgroundWhile studies have demonstrated favorable outcomes in utilization of primary total shoulder arthroplasty (TSA) for the treatment of glenohumeral osteoarthritis (OA), adverse events such as infections can still occur. Periprosthetic joint infections (PJIs) are associated with worse outcomes and patient morbidity. The purpose of this study was to: (1) compare patient demographics amongst TSA patients with and without PJIs following primary TSA; and (2) identify patient-related risk factors for PJIs following primary TSA.MethodsPatients undergoing primary TSA for the treatment of glenohumeral OA were identified using the Mariner administrative claims database by CPT code 23,472. Laterality modifiers were utilized to ensure PJIs were developing in the correct laterality as those patients undergoing primary TSA. Inclusion for the study group consisted of patients who developed PJIs within 2-years after the index procedure, whereas patients who did not develop PJIs served as the comparison cohort. Primary outcomes analyzed included patient demographics and patient-related risk factors for PJIs following primary TSA. A stepwise backwards elimination multivariate binomial logistic regression analyses was performed to determine the odds (OR) of PJIs in patients undergoing primary TSA. A P value less than .05 was considered statistically significant.ResultsThe query yielded 15,396 patients who underwent primary TSA for glenohumeral OA, of which 191 patients developed PJIs and 15,205 did not develop PJIs. The study found statistically significant differences amongst patients who did and did not develop PJIs following primary TSA with respect to age, sex, and presence of comorbid conditions. Risk factors associated with developing PJIs following primary TSA included: pathologic weight loss (OR: 2.06, P < .0001), obesity (OR: 1.56, P = .0001), male sex (OR: 1.52, P = .007), and peripheral vascular disease (OR: 1.46, P = .022).ConclusionAs the number of primary TSAs for the treatment of glenohumeral OA increase worldwide, identifying modifiable risk-factors to reduce the incidence of infection is critical. The study found various modifiable and non-modifiable risk factors associated with developing PJIs following primary TSA. This study is valuable to orthopedists in order to identify and risk-stratify patients with regard to PJI in the setting of primary TSA for OA.Level of EvidenceLevel III; Case-Control Study  相似文献   
6.
目的探讨新型布尼亚病毒感染后患者发热伴血小板减少症状(SFTS)发病期和恢复期的凝血和血栓相关指标及其临床意义。方法选择2020年4月12日至8月12日在安徽医科大学第一附属医院收治的新型布尼亚病毒感染后SFTS患者,其中SFTS发病期36例,SFTS恢复期18例,并招募36名健康人作为健康对照组,采集血浆标本。回顾性分析血浆凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原含量(FIB)、血浆凝血酶时间(TT)、抗凝血酶-Ⅲ(AT-Ⅲ)、纤维蛋白降解产物(FDP)、D-二聚体(D-D)、血栓调节蛋白(TM)、凝血酶-抗凝血酶复合物(TAT)、纤溶酶-α2纤溶酶抑制物复合物(PIC)、组织型纤溶酶原激活剂-抑制剂1复合物(t-PAIC)浓度。统计比较3组间上述指标的差异。结果与健康对照组比较,SFTS发病组PT[12.5(12.1,13.6)s比10.8(10.5,11.5)s,P<0.05]较长,但仍在正常参考值范围内(14.0~21.0 s);APTT[49.1(42.0,58.2)s比28.5(26.6,30.4)s,P<0.05]较长;FDP[6.07(2.67,8.64)μg/ml比1.00(0.80,1.87)μg/ml]和D-D[2.27(1.04,2.98)μg/ml比0.30(0.21,0.47)μg/ml]较高(P均<0.001);血浆TAT[16.05(8.05,26.58)ng/ml比3.55(2.60,4.85)ng/ml]和PIC浓度[4.44(2.52,5.54)μg/ml比0.84(0.60,1.35)μg/ml]较高(P均<0.001);TM[(19.41±8.29)TU/ml比(9.33±1.89)TU/ml]和t-PAIC浓度[(37.52±21.10)ng/ml比(7.06±3.37)ng/ml]较高(P均<0.001)。SFTS恢复组患者血浆中TAT浓度为9.10(3.95,18.40)ng/ml,仍高于正常参考范围(<4 ng/ml),PIC浓度低于SFTS发病组[1.91(1.45,2.93)μg/ml比4.44(2.52,5.54)μg/ml,P<0.05],TM和t-PAIC低于SFTS发病组(P均<0.05)。结论SFTS患者发病期机体凝血系统激活,血管内皮受到损伤;恢复期血管内皮损伤情况减轻,但机体依然存在一定程度的凝血系统障碍,提示当体内病毒清除后,仍需继续监测凝血指标。  相似文献   
7.
崔亚琼  刘薇 《天津医药》2022,50(12):1340-1344
儿童多系统炎症综合征(MIS-C)是一种合并多器官功能受损的全身炎症综合征,大多数患儿存在新型冠状病毒(SARS-CoV-2)感染证据或新型冠状病毒肺炎(COVID-19)患者接触史。患儿常出现发热、胃肠道症状、心功能异常及休克等表现。细胞因子风暴(CS)是由外界刺激触发的全身性炎症反应,引起CS的诱因包括医源性、病源性、单基因或自身免疫性疾病等。MIS-C发病机制尚未完全明确,可能与SARS-CoV-2感染后引起的机体过度免疫反应有关。就COVID-19感染相关MIS-C的临床特征和CS的发生及诱因予以综述,并讨论两者间的关系,以期为MIS-C的机制研究和临床诊断提供参考。  相似文献   
8.
Mucormycosis is caused by the fungi belonging to the order Mucorales and class Zygomycetes. The incidence of mucormycosis has increased with the onset of the severe acute respiratory syndrome coronavirus 2 infections leading to the coronavirus disease 2019 (COVID-19) pandemic. This rise is attributed to the use of immunosuppressive medication to treat COVID-19 infections. Authors have retrospectively collected data of our cases of mucormycosis diagnosed from April 2020 to April 2021 at our institute. A total of 20 patients with rhinocerebral mucormycosis were studied. Most of the study subjects were male patients (90%) and were of the age group 41-50 years. Most patients in the review had comorbidities (85%) with diabetes being the most common comorbidity. Para nasal sinuses were involved in all the cases. Involvement of the neck spaces was present in 60% of the cases. Involvement of the central nervous system was present in 80% of the cases. Orbital involvement was present in 90% of the cases. The authors reviewed the various imaging findings of mucormycosis on computed tomography and magnetic resonance imaging in this article.  相似文献   
9.
10.
ObjectiveTo describe effectiveness of mRNA vaccines by comparing 2-dose (2D) and 3-dose (3D) healthcare worker (HCW) recipients in the setting of Omicron variant dominance. Performance of 2D and 3D vaccine series against SARS-CoV-2 variants and the clinical outcomes of HCWs may inform return-to-work guidance.MethodsIn a retrospective study from December 15, 2020 to January 15, 2022, SARS-CoV-2 infections among HCWs at a large tertiary cancer centre in New York City were examined to estimate infection rates (aggregated positive tests / person-days) and 95% CIs over the Omicron period in 3D and 2D mRNA vaccinated HCWs and were compared using rate ratios. We described the clinical features of post-vaccine infections and impact of prior (pre-Omicron) COVID infection on vaccine effectiveness.ResultsAmong the 20857 HCWs in our cohort, 20,660 completed the 2D series with an mRNA vaccine during our study period and 12461 had received a third dose by January 15, 2022. The infection rate ratio for 3D versus 2D vaccinated HCWs was 0.667 (95% CI 0.623, 0.713) for an estimated 3D vaccine effectiveness of 33.3% compared to two doses only during the Omicron dominant period from December 15, 2021 to January 15, 2022. Breakthrough Omicron infections after 3D + 14 days occurred in 1,315 HCWs. Omicron infections were mild, with 16% of 3D and 11% 2D HCWs being asymptomatic.DiscussionStudy demonstrates improved vaccine-derived protection against COVID-19 infection in 3D versus 2D mRNA vaccinees during the Omicron surge. The advantage of 3D vaccination was maintained irrespective of prior COVID-19 infection status.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号